Depixus raises €30.6m in Series A financing
Biotechnology company Depixus has completed an oversubscribed Series A financing which raised €30.6 million.
Paris-headquartered Depixus is developing a technology for the fast, accurate and straightforward extraction of multiomic information from DNA, RNA, and proteins. Funds from the financing will enable Depixus to continue developing its proprietary Magna instrument system, workflows and reagents towards commercial launch.
Depixus is a portfolio company of Arix Bioscience, a London-based venture capital company focused on investing in and building breakthrough biotech companies. Having participated in the first tranche of the Series A financing in February this year, investing €2.7 million, Arix now has a 14.2% fully diluted ownership stake in Depixus.
Mark Chin, managing director at Arix and Depixus board director, said: “This is an exciting time for Depixus as it moves forward with its goal to commercialise a highly innovative technology platform for the fast, accurate and inexpensive extraction of genetic and epigenetic information from single molecules of DNA and RNA. Arix is committed to building breakthrough biotech companies, and it is a privilege to work alongside such a distinguished team of entrepreneurs and co-investors.”